Related Experiment Videos
Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study
B Combe1, P Goupille, J L Kuntz
1Hôpital Lapeyronie, CHU Montpellier-Nîmes, France.
British Journal of Rheumatology
|July 1, 1996
Summary
This study found that sulphasalazine (SSZ) significantly reduced pain in psoriatic arthritis patients compared to placebo over 24 weeks. While generally safe, SSZ
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory condition.
- Effective and safe treatments for PsA are crucial.
Purpose of the Study:
- To evaluate the efficacy and tolerability of sulphasalazine (SSZ) versus placebo in PsA patients.
- To assess SSZ's impact on pain, joint and skin symptoms, and inflammatory markers.
Main Methods:
- Prospective, double-blind, placebo-controlled, randomized study.
- 120 PsA patients received SSZ (2.0 g/day) or placebo for 24 weeks.
- Efficacy assessed via pain, patient global assessment, morning stiffness, Ritchie articular index, ESR, and CRP.
Main Results:
- Pain was the only statistically significant primary outcome favoring SSZ in intention-to-treat analysis.
- No significant differences observed in other clinical or biological variables, though trends favored SSZ.
- Sulphasalazine (SSZ) demonstrated a favorable safety profile at 2.0 g/day.
Conclusions:
- Sulphasalazine (SSZ) at 2.0 g/day is a safe treatment option for psoriatic arthritis.
- Efficacy was primarily demonstrated for pain reduction in this study.
- Further research may explore optimal dosing or combination therapies.